Immatics Announces Full Year 2023 Financial Results and Corporate Update
Interim clinical data update on ACTengine® IMA203 GEN1 (PRAME) in melanoma at RP2D in November 2023: 50% confirmed objec…
Interim clinical data update on ACTengine® IMA203 GEN1 (PRAME) in melanoma at RP2D in November 2023: 50% confirmed objec…
New partnership will harness Moderna’s mRNA rapid-response platform, clinically validated during the COVID-19 pandemic,…
Phase 1/2 clinical trial initiated evaluating Immatics’ second next-generation half-life extended TCR Bispecific program…
. If gold is brought down to nanoparticle size, it appears purple. Thus, due to a change in the refraction of light, go…
Eckert & Ziegler (ISIN DE0005659700, TecDAX) announced that the Clinical Trial Notification (CTN) of a joint clinical st…
ACTengine® patient recruitment remains on track; as of end of July, a total of 27 patients have been treated with IMA201…
Prof. Dr. Jessica C. Hassel, Principle Investigator of the SENSITIZE study at the University Hospital Heidelberg, German…
»Our team has delivered an outstanding performance in a rather complex environment. I am grateful to be able to hand ove…
»Das Team hat trotz eines komplexen Umfelds eine hervorragende Leistung abgeliefert. Ich bin dankbar, so ein starkes Unt…
Immatics, a leading company in the field of cancer immunotherapy, today announced the completion of its Series E financi…